Information date: 12 November 2026 — China’s R&D super-deduction is a self-assessment, not an approval. A manufacturing enterprise expenses qualifying R&D cost at 100% and then claims a further 100%, reported on Form A107012 inside the annual corporate income tax return. No bureau signs off in advance. The taxpayer instead builds a retention file that must survive an examination two or three years later, tracing each project from a management resolution through personnel time sheets, direct material and fuel consumption, depreciation of instruments, amortisation of intangibles, and the ‘other related expenses’ bucket capped at 10% of total qualifying R&D expense. Firms in the negative-list industries are excluded regardless of how genuine the science is. If the entity is manufacturing and outside the negative list, claim and build the file concurrently rather than afterwards. If the entity sits inside a negative list but a subsidiary does not, decide before year end whether the R&D belongs in the other legal entity. If R&D is genuinely entangled with production, either separate the cost centres or file a deliberately conservative claim. If a project has no initiation document, do not claim it this year — write the document for the next one.
Verified facts and scope
China’s R&D super-deduction is a self-assessment, not an approval. A manufacturing enterprise expenses qualifying R&D cost at 100% and then claims a further 100%, reported on Form A107012 inside the annual corporate income tax return. No bureau signs off in advance. The taxpayer instead builds a retention file that must survive an examination two or three years later, tracing each project from a management resolution through personnel time sheets, direct material and fuel consumption, depreciation of instruments, amortisation of intangibles, and the ‘other related expenses’ bucket capped at 10% of total qualifying R&D expense. Firms in the negative-list industries are excluded regardless of how genuine the science is.
Scope has to be fixed before the numbers mean anything: List every R&D project with start and end dates, the industry code on the business licence, and whether the entity counts as manufacturing (100% additional) or not. Then test negative-list status: tobacco manufacturing, accommodation and catering, wholesale and retail, real estate, leasing and business services, and entertainment are excluded even for real R&D. Finally check whether any cost was capitalised as an intangible asset, because that route amortises rather than expenses and changes the form. Anything outside that set is a separate question with its own evidence requirement, and mixing the two is the most common way a workable plan turns into an unusable one.
For a decision on “Resources: Where to Verify Each Line of a China R&D Super-Deduction Claim — the 100% Additional Deduction for Manufacturing, the Negative-List Industries and the Form A107012 Trail a Foreign-Invested Plant Must Leave Behind”, keep three layers apart: the published rule or statistic, the company’s own orders and process records, and the assumptions nobody has tested yet. The first layer defines the external conditions, the second proves what is true for this business, and the third is where the risk actually sits. Public material cannot substitute for a contract, a system log, a sample or a live test.
A practical way to test the scope is to ask which parts of “Resources: Where to Verify Each Line of a China R&D Super-Deduction Claim — the 100% Additional Deduction for Manufacturing, the Negative-List Industries and the Form A107012 Trail a Foreign-Invested Plant Must Leave Behind” would still be true if the company changed supplier, entity or product line tomorrow. Items that survive that change belong to the rule layer and can be taken from official publications; items that do not survive belong to the operating layer and have to be rebuilt from invoices, warehouse records, customs entries or platform statements. Where List every R&D project with start and end dates, the industry code on the business licence, and whether the entity counts as manufacturing (100% additional) or not. Then test negative-list status: tobacco manufacturing, accommodation and catering, wholesale and retail, real estate, leasing and business services, and entertainment are excluded even for real R&D. Finally check whether any cost was capitalised as an intangible asset, because that route amortises rather than expenses and changes the form, the two layers are frequently mistaken for each other, and an action plan built on the wrong one either over-complies or misses a deadline it never saw coming.
How the effect reaches operations
The model is trust-then-verify. At filing time the only artefact that exists is paper, and the examination question is never ‘is the R&D real’ but ‘can the R&D be reconstructed from records’. Projects without an initiation resolution, without a separate cost centre, or staffed by people who also work the production line fail on evidentiary grounds rather than technical ones. That is why the verification work happens before the year closes, not after a notice arrives.
Failures are usually structural rather than fraudulent: production staff counted as R&D staff; trial-production output sold without reducing the qualifying base; other related expenses pushed past the 10% cap; equipment depreciation allocated by headcount instead of actual use; negative-list status missed because the licence carries a wholesale code next to a manufacturing one. A second family is timing — cost booked in the wrong year, or a project closed in the ledger but still claimed on the form.
Translated into an operating sequence, The model is trust-then-verify. At filing time the only artefact that exists is paper, and the examination question is never ‘is the R&D real’ but ‘can the R&D be reconstructed from records’. Projects without an initiation resolution, without a separate cost centre, or staffed by people who also work the production line fail on evidentiary grounds rather than technical ones. That is why the verification work happens before the year closes, not after a notice arrives. That ordering matters: check applicability first, then the transmission step, and only then the size of the gap in cost or timing. When an intermediate step cannot be confirmed, the honest response is to narrow the scope of the conclusion rather than to substitute an industry average for the company’s own figures.
The cost of getting the order wrong is asymmetric. A team that checks applicability too late usually discovers it at the point where the shipment, the filing or the invoice can no longer be changed without penalty, and by then the only remaining lever is price. A team that checks early spends a few hours on questions that turn out to be irrelevant, which is cheap by comparison. On “Resources: Where to Verify Each Line of a China R&D Super-Deduction Claim — the 100% Additional Deduction for Manufacturing, the Negative-List Industries and the Form A107012 Trail a Foreign-Invested Plant Must Leave Behind” the practical rule is therefore to spend the first hour on scope and the second on the numbers, never the other way round.
Decision
If the entity is manufacturing and outside the negative list, claim and build the file concurrently rather than afterwards. If the entity sits inside a negative list but a subsidiary does not, decide before year end whether the R&D belongs in the other legal entity. If R&D is genuinely entangled with production, either separate the cost centres or file a deliberately conservative claim. If a project has no initiation document, do not claim it this year — write the document for the next one.
The conditions should be written down so the decision can be re-run by someone else: List every R&D project with start and end dates, the industry code on the business licence, and whether the entity counts as manufacturing (100% additional) or not. Then test negative-list status: tobacco manufacturing, accommodation and catering, wholesale and retail, real estate, leasing and business services, and entertainment are excluded even for real R&D. Finally check whether any cost was capitalised as an intangible asset, because that route amortises rather than expenses and changes the form. When those hold, proceed as described; when one is missing, close the gap first and decide afterwards. This is a research summary, not tax, accounting or legal advice. Rates, forms and retention requirements change; verify against current SAT and MOF announcements and your own filing position before acting.
Two workstreams usually have to move in parallel. The compliance workstream closes the document side of “Resources: Where to Verify Each Line of a China R&D Super-Deduction Claim — the 100% Additional Deduction for Manufacturing, the Negative-List Industries and the Form A107012 Trail a Foreign-Invested Plant Must Leave Behind” — registrations, confirmations, filings — while the commercial workstream protects the delivery date, the pricing already quoted and the customer commitments that were made on the earlier reading of the rules. Running them as one queue is how small documentation gaps become missed shipment dates: the commercial side waits for a certificate that could have been requested a week earlier. If the entity is manufacturing and outside the negative list, claim and build the file concurrently rather than afterwards. If the entity sits inside a negative list but a subsidiary does not, decide before year end whether the R&D belongs in the other legal entity. If R&D is genuinely entangled with production, either separate the cost centres or file a deliberately conservative claim. If a project has no initiation document, do not claim it this year — write the document for the next one. Set one owner per workstream and one shared status sheet, and treat a red item on either side as a reason to freeze only the affected order.
Implementation checklist
- Map every project to an initiation resolution and a dedicated cost centre.
- Test the licence industry code against the negative list before filing.
- Reconcile Form A107012 to the general ledger R&D account line by line.
- Name one decision owner, one execution owner and one review date.
- Keep the source page, access date, entity and internal evidence.
- On any change, reopen only the affected judgement.
Evidence and review
Start with the smallest test that can change the answer: Map every project to an initiation resolution and a dedicated cost centre. Pick one real entity or one representative case, write down the continue, watch and stop conditions in advance, and record the input version, the owner, the start time and the actual result. The first pass should only look at facts that move the decision; formatting preferences are not risk.
The second pass is completed by “Test the licence industry code against the negative list before filing”, and someone who did not prepare the file should spot-check one piece of critical evidence. Failures are usually structural rather than fraudulent: production staff counted as R&D staff; trial-production output sold without reducing the qualifying base; other related expenses pushed past the 10% cap; equipment depreciation allocated by headcount instead of actual use; negative-list status missed because the licence carries a wholesale code next to a manufacturing one. A second family is timing — cost booked in the wrong year, or a project closed in the ledger but still claimed on the form. A single small deviation can be corrected in place; a repeated deviation, or one that touches a statutory duty or changes the economics, is what justifies pausing the affected part.
After “Reconcile Form A107012 to the general ledger R&D account line by line”, compare the actual result with the baseline rather than with the impression of the team. If the entity is manufacturing and outside the negative list, claim and build the file concurrently rather than afterwards. If the entity sits inside a negative list but a subsidiary does not, decide before year end whether the R&D belongs in the other legal entity. If R&D is genuinely entangled with production, either separate the cost centres or file a deliberately conservative claim. If a project has no initiation document, do not claim it this year — write the document for the next one. When the arrangement is extended to more products, customers or processes, keep the same success test and one complete record per batch. If later information changes, update only the affected fields.
One last discipline keeps the file usable next quarter: write the closing note as if a colleague who has never spoken to the supplier has to act on it. That note states what was verified, on which date, against which source, and what remains open — on “Resources: Where to Verify Each Line of a China R&D Super-Deduction Claim — the 100% Additional Deduction for Manufacturing, the Negative-List Industries and the Form A107012 Trail a Foreign-Invested Plant Must Leave Behind” it also states which of the three actions was actually finished and which was only scheduled. Teams that skip the closing note re-litigate the same question every month, and each round costs more than the documentation would have. This is a research summary, not tax, accounting or legal advice. Rates, forms and retention requirements change; verify against current SAT and MOF announcements and your own filing position before acting.
Limits of the conclusion
This is a research summary, not tax, accounting or legal advice. Rates, forms and retention requirements change; verify against current SAT and MOF announcements and your own filing position before acting.
The limits are structural rather than cautious wording. Public sources describe rules and market conditions; they do not observe “Resources: Where to Verify Each Line of a China R&D Super-Deduction Claim — the 100% Additional Deduction for Manufacturing, the Negative-List Industries and the Form A107012 Trail a Foreign-Invested Plant Must Leave Behind” inside a specific company. Where the analysis quotes a second-hand interpretation, the original release has to remain reachable, and a figure that cannot be traced back does not enter the decision table. Where the point depends on List every R&D project with start and end dates, the industry code on the business licence, and whether the entity counts as manufacturing (100% additional) or not. Then test negative-list status: tobacco manufacturing, accommodation and catering, wholesale and retail, real estate, leasing and business services, and entertainment are excluded even for real R&D. Finally check whether any cost was capitalised as an intangible asset, because that route amortises rather than expenses and changes the form, the conclusion is only as current as the last check of those conditions.
